Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $163.4 million.

  • Arrowhead Pharmaceuticals' Other Working Capital Changes rose 1175185.45% to $163.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $174.7 million, marking a year-over-year increase of 600601.76%. This contributed to the annual value of $9.9 million for FY2025, which is 34370.54% up from last year.
  • As of Q4 2025, Arrowhead Pharmaceuticals' Other Working Capital Changes stood at $163.4 million, which was up 1175185.45% from -$13.0 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Other Working Capital Changes ranged from a high of $163.4 million in Q4 2025 and a low of -$76.2 million during Q1 2023
  • Moreover, its 5-year median value for Other Working Capital Changes was -$969500.0 (2024), whereas its average is $50699.9.
  • In the last 5 years, Arrowhead Pharmaceuticals' Other Working Capital Changes crashed by 12328990.62% in 2023 and then surged by 1175185.45% in 2025.
  • Arrowhead Pharmaceuticals' Other Working Capital Changes (Quarter) stood at $30420.0 in 2021, then tumbled by 75639.12% to -$23.0 million in 2022, then surged by 116.52% to $3.8 million in 2023, then crashed by 136.93% to -$1.4 million in 2024, then skyrocketed by 11751.85% to $163.4 million in 2025.
  • Its last three reported values are $163.4 million in Q4 2025, -$13.0 million for Q3 2025, and -$20.3 million during Q2 2025.